Skip to Content

Join the 'Raptiva' group to help and get support from people like you.

Raptiva News

Kidney Woes Tied to Raised Cancer Risk, Study Finds

Posted 12 Nov 2015 by

THURSDAY, Nov. 12, 2015 – Kidney failure and having a kidney transplant may increase the risk for certain types of cancer, a new study suggests. Poor kidney function and immune system-suppressing drugs may be behind this increased risk, according to Elizabeth Yanik, of the U.S. National Cancer Institute, and colleagues. For the study, published in the Nov. 12 online edition of the Journal of the ...

FDA Medwatch Alert: Raptiva (efalizumab)

Posted 8 Apr 2009 by

[UPDATE 04/08/2009] Genentech and FDA notified healthcare professionals of the voluntary, phased withdrawal of Raptiva, a medication for treatment of psoriasis, from the U.S. market due to a potential risk to patients of developing progressive multifocal leukoencephalopathy (PML). By June 8, 2009, Raptiva will no longer be available in the United States. Prescribers are being asked not to ...

FDA Medwatch Alert: Raptiva (efalizumab)

Posted 19 Feb 2009 by

[Posted 02/19/2009] FDA issued a Public Health Advisory to notify healthcare professionals of three confirmed, and one possible report of progressive multifocal leukoencephalopathy (PML), a rare brain infection, in patients using the psoriasis drug Raptiva. In October 2008, the labeling for Raptiva was changed to highlight, in a Boxed Warning, the risks of life-threatening infections, including ...

FDA Medwatch Alert: Raptiva (efalizumab) - Oct 17, 2008

Posted 17 Oct 2008 by

[Posted 10/17/2008] FDA notified healthcare professionals of extensive labeling changes, including a Boxed Warning, to highlight the risks of life-threatening infections, including bacterial sepsis, viral meningitis, invasive fungal disease, progressive multifocal leukoencephalopathy and other opportunistic infections with the use of Raptiva. In addition, the prescribing information will be ...

FDA Medwatch Alert: Raptiva (efalizumab) - Jun 20, 2005

Posted 20 Jul 2005 by

[Posted 07/20/2005] Genentech and FDA revised the WARNINGS, ADVERSE REACTIONS sections and Patient Information Sheet for RAPTIVA (efalizumab), indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Healthcare professionals and patients were informed about reports of immune-mediated ...

Psoriasis Drug Raptiva Pulled From U.S. Market

Posted 8 Apr 2009 by

WEDNESDAY, April 8 – The troubled psoriasis drug Raptiva is being withdrawn from the U.S. market, California-based drug maker Genentech announced Wednesday. The move comes almost two months after U.S. health officials issued a public health advisory on the drug after confirming a link to a rare, sometimes fatal brain infection. In a prepared release, Genentech said Wednesday, "Effective ...

FDA Warns Users on Psoriasis Drug

Posted 19 Feb 2009 by

THURSDAY, Feb. 19 – U.S. health officials issued a public health advisory Thursday for the psoriasis drug Raptiva after confirming that three people using the medication have died. Two of three people with confirmed cases of a rare brain infection called progressive multifocal leukoencephalopathy (PML) are among the dead, according to the U.S. Food and Drug Administration advisory. The third ...

Ask a Question

Further Information

Related Condition Support Groups

Plaque Psoriasis, Psoriasis

Raptiva Patient Information at